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The development of the microbiome from infancy to childhood is 
dependent on a range of factors, with microbial–immune crosstalk 
during this time thought to be involved in the pathobiology of later 
life diseases1–9 such as persistent islet autoimmunity and type 1 
diabetes10–12. However, to our knowledge, no studies have performed 
extensive characterization of the microbiome in early life in a large, 
multi-centre population. Here we analyse longitudinal stool samples 
from 903 children between 3 and 46 months of age by 16S rRNA gene 
sequencing (n = 12,005) and metagenomic sequencing (n = 10,867), 
as part of the The Environmental Determinants of Diabetes in the 
Young (TEDDY) study. We show that the developing gut microbiome 
undergoes three distinct phases of microbiome progression: a 
developmental phase (months 3–14), a transitional phase (months 
15–30), and a stable phase (months 31–46). Receipt of breast milk, 
either exclusive or partial, was the most significant factor associated 
with the microbiome structure. Breastfeeding was associated with 
higher levels of Bifidobacterium species (B. breve and B. bifidum), 
and the cessation of breast milk resulted in faster maturation of the 
gut microbiome, as marked by the phylum Firmicutes. Birth mode 
was also significantly associated with the microbiome during the 
developmental phase, driven by higher levels of Bacteroides species 
(particularly B. fragilis) in infants delivered vaginally. Bacteroides 
was also associated with increased gut diversity and faster 
maturation, regardless of the birth mode. Environmental factors 
including geographical location and household exposures (such as 
siblings and furry pets) also represented important covariates. A 
nested case–control analysis revealed subtle associations between 
microbial taxonomy and the development of islet autoimmunity or 
type 1 diabetes. These data determine the structural and functional 
assembly of the microbiome in early life and provide a foundation 
for targeted mechanistic investigation into the consequences of 
microbial–immune crosstalk for long-term health.
In this study, a total of 12,500 stool samples from 903 children from 
three European countries (Germany, Sweden and Finland) and three 
US states (Colorado, Georgia and Washington) were analysed. The chil-
dren represent those who seroconverted to islet cell autoantibody pos-
itivity or developed type 1 diabetes (T1D) and matched controls. Stool 
samples were collected, on average, monthly from around 3 months of 
age as part of the The Environmental Determinants of Type 1 Diabetes 
in the Young (TEDDY) study13. After rarefaction and limiting sam-
ples to 3–46 months of age, we analysed the microbiome (16S rRNA 
gene sequencing, n = 12,005 samples from 903 children; metagenomic 
sequencing, n = 10,867 samples from 783 children) and functional 
metagenome (metagenomic sequencing only) from longitudinal stool 
samples (Extended Data Table 1). A companion paper by Vatanen 
et al.14 focused exclusively on metagenomic sequencing data.
In this cohort of children that are at-risk for developing islet auto-
immunity (IA) or T1D, we aimed to (1) characterize definitively the 
longitudinal gut microbiome development from 3 to 46 months of age; 
(2) determine selected maternal and postnatal influences on the developing 
bacterial community during this same time period of early development; 
and (3) use a nested case–control analysis to investigate the potential of the 
microbiome as a predictor for the development of IA or T1D.
A general overview of bacterial taxonomic and functional pathway 
development is provided in Supplementary Note 1 and Extended Data 
Fig. 1. Dirichlet multinomial mixtures (DMM) modelling was applied 
to 16S rRNA gene sequencing (Fig. 1) and metagenomic sequencing 
data (Extended Data Fig. 2). All samples from 3 to 46 months of age 
were included, and 16S rRNA gene sequencing profiles formed ten 
clusters (based on lowest Laplace approximation) (Fig. 1a). Bacterial 
richness and diversity increased in each cluster (Fig. 1a, b). Using linear 
mixed-effects modelling of the top five phyla and Shannon’s diversity 
index, we determined three distinct phases of microbiome progression: 
a developmental phase (months 3–14), a transitional phase (months 
15–30), and a stable phase (≥31 months), in which all five phyla and 
the Shannon diversity index changed significantly during the devel-
opmental phase, two phyla (Proteobacteria and Bacteroidetes) and the 
Shannon diversity index changed significantly during the transitional 
phase, and all phyla and the Shannon diversity index were unchanged 
during the stable phase (Fig. 1c). Bifidobacterium dominated during the 
initial developmental phase, in which 20% of individuals transitioned 
from cluster 1 to cluster 3 (Bifidobacterium was dominant in both 
clusters). As infants aged, the microbiomes of their stools diversified 
into clusters 4–8 during months 15–30 (that is, the transitional phase). 
Microbiome stabilization, in which infants’ samples remained in the 
same cluster at consecutive time points, was observed from month 31 
of life. Clusters 8–10 were the most dominant during the stable phase, 
with these clusters characterized by high alpha diversity and dominance 
of genera within the Firmicutes phyla. The three microbiome phases 
and changes in taxa are consistent with other cohorts15–18 and were 
supported by the metagenomic sequencing data (Supplementary Note 2 
and Extended Data Fig. 2).
We next sought to determine the significant factors associated with 
the microbiome profiles from 16S rRNA gene sequencing (genus level), 
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metagenomic sequencing taxa (species level), and functional metabolic 
capacity (Kyoto encyclopedia of genes and genomes (KEGG) mod-
ules) (Supplementary Table 1). For statistical analysis, covariates were 
analysed by stratifying the samples into discrete time points (months 
3–6, 7–10, 11–14, 15–18, 19–22, 23–26, 27–30 and 31–40), and only 
the first sample from each infant was included. Information about 
the underlying grouping of each covariate is shown in Extended Data 
Table 1. Several covariates were significantly associated with the genus 
and species level bacterial community profiles between months 3 and 
18 of age, particularly at the first time point of 3 to 6 months (Fig. 2). 
Conversely, bacterial metabolic potential was associated exclusively 
with the consumption of breast milk from months 3 to 14 of life (Fig. 2).
Breastfeeding explained the greatest amount of variance from months 
3 to 14 of life, after which only 10% of infants received any breast milk 
(Fig. 2). Breastfeeding had a comparable influence on microbiome 
development, regardless of whether it was exclusive or together with 
formula milk and/or solids (Fig. 3a). At the genus level, the receipt 
of breast milk was most significantly associated with Bifidobacterium 
throughout each time window (Supplementary Table 2). At the spe-
cies level, breastfeeding was significantly associated with 121 different 
bacterial species, with higher levels of B. bifidum, B. breve, B. den-
tium, Lactobacillus rhamnosus and Staphylococcus epidermidis, and 
lower levels of Escherichia coli, Tyzzerella nexilis, Eggerthella lenta, 
Ruminococcus torques and Roseburia intestinalis in infants that were 
breastfed (a full list of significant taxa and associated P values are shown 
in Supplementary Table 2). Bifidobacterium spp. and Lactobacillus 
spp. exist viably in breast milk and Staphylococcus spp. colonize the 
areolar skin, thus these species can be directly transferred from the 
mother to infant19–22. B. longum was not significantly associated with 
breastfeeding and remained in higher relative abundance compared to 
other Bifidobacterium spp. (Fig. 3b). In the companion manuscript by 
Vatanen et al.14, most B. longum strains were found to contain genes 
from the human milk oligosaccharide (HMO) gene cluster, whereas 
after the cessation of breast milk, most B. longum strains no longer 
carried these genes. This potentially reflects the ability of B. longum 
subsp. infantis and subsp. longum to use mammalian- and plant-derived 
oligosaccharides, respectively23,24. B. bifidum also persisted after the 
cessation of breastfeeding, and this species is able to switch HMO to 
mucin degradation24. Vatanen et al.14 show experimentally that B. breve, 
B. longum and B. bifidum, which make up DMM clusters 1–3 (Extended 
Data Fig. 2), have distinct profiles of sugar utilization, suggesting that 
the different nutrient availability between infants can promote the col-
onization of specific Bifidobacterium species.
As the infant ages, the proportion of solid foods in the diet increases 
(and the amount of breast milk decreases)21. In the current study, the 
Shannon diversity index between infants receiving some breast milk 
and infants no longer receiving breast milk began to converge over 
time, probably as a result of a reduced proportion of breast milk in the 
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Fig. 1 | DMM clustering of 16S rRNA gene sequencing data (n = 12,005). 
The entire dataset formed ten distinct clusters based on lowest Laplace 
approximation. a, Heat map showing the relative abundance of the 25 
most dominant bacterial genera per DMM cluster. Taxa names in square 
brackets are in need of formal taxonomic revision. b, Box plots showing 
the alpha diversity (richness and Shannon’s diversity) per each DMM 
cluster. The centre line denotes the median, the boxes cover the 25th and 
75th percentiles, and the whiskers extend to the most extreme data point, 
which is no more than 1.5 times the length of the box away from the box. 
Points outside the whiskers represent outlier samples. c, Transition model 
showing the progression of samples through each DMM cluster per each 
time point, from months 3 to 46 of life. Dashed boxes show the three 
phases of microbiome progression (developmental, transitional and stable 
phase). Solid squares next to the labels denote the significant changes 
in phyla and Shannon’s diversity (H') per phase based on multiple linear 
regression. All phyla and the H' were significant in the developmental 
phase, two phyla and the H' were significant in the transitional phase, and 
no phyla or the H' were in the stable phase. Nodes and edges are sized 
based on the total counts. Nodes are coloured according to DMM cluster 
number and edges are coloured by the transition frequency. Transitions 
with less than 4% frequency are not shown. Results are further supported 
by the metagenomic sequencing data in Extended Data Fig. 2.
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diet and therefore less dominance of Bifidobacterium (Fig. 3c). Infants 
receiving some breast milk had significantly lower diversity when com-
pared with infants no longer receiving breast milk across all phases 
(P < 0.001 for all phases), owing to the dominance of Bifidobacterium 
in infants receiving breast milk. To explore microbiome maturation 
further, we used microbiota age and microbiota-by-age Z-scores 
(MAZ) as previously described25, with a model of 20 operational taxo-
nomic units (OTUs) that explained 72% of the variance (compared to 
74% when including all OTUs in the model) (Extended Data Fig. 3). 
Comparably, the microbiota age and MAZ scores were significantly 
reduced in infants receiving some breast milk in the developmental 
and transitional phases (both P < 0.001 for microbiota age and MAZ 
scores), but converged in the stable phase (microbiota age P = 0.331 
and MAZ score P = 0.196) (Fig. 3d). After the cessation of breast milk, 
110 unique bacterial species (89 from the Firmicutes phylum) were sig-
nificantly increased from months 3 to 14 of life alone (Supplementary 
Table 2). The suppression of Firmicutes while in receipt of some breast 
milk was recently noted21. Together, these data support existing reports 
that the maturation of the gut microbiome is driven by the cessation of 
breast milk (rather than the introduction of solid foods), hallmarked 
by increased levels of Firmicutes17,21,26.
Breastfeeding was the only covariate that was significantly associ-
ated with metabolic potential (Fig. 2). Plotting all significant modules 
(Supplementary Table 1) from the first three time points (months 
3–14) showed clear clustering based on the receipt of breast milk, 
with comparability in the metabolic capacity regardless of the time 
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Fig. 2 | Significance and explained variance of 22 microbiome 
covariates modelled by EnvFit across all data types. Horizontal bars 
show the amount of variance (r2) explained by each covariate in the model 
as determined by EnvFit. The groups within each covariate are detailed in 
Extended Data Table 1. Covariates are coloured based on overall metadata 
group. Significant covariates (false discovery rate (FDR) P < 0.05) are 
represented in bold font. Asterisk denotes the significant covariates at each 
time point. BMI, body mass index; wtgain, weight gain. a, Microbiome 
profiles at the genus level based on 16S rRNA gene sequencing data 
(n = 4,069). b, Microbiome profiles at the species level based on 
metagenomic sequencing (n = 3,843). c, Functional metagenomic capacity 
at the module level based on metagenomic sequencing (n = 3,843).
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point (Fig. 3e). Modules most significantly associated with breastfed 
infants were from the ‘carbohydrate and lipid metabolism’ pathway 
and included ‘fatty acid biosynthesis’ (M00083 and M00082) and ‘beta- 
oxidation, acyl-CoA synthesis’ (M00086) (Supplementary Table 2). 
This is in accordance with previous work that found that genes that 
relate to the biosynthesis of fatty acids are increased during infancy in 
breastfed infants17,27,28. Conversely, infants not receiving breast milk 
showed rapid turnover of the metabolic capacity, and the ‘dicarboxylate- 
hydroxybutyrate cycle’ (M00374) and ‘reductive acetyl-CoA (Wood–
Ljungdahl)’ (M00377) pathways were increased. Modules relating 
to vitamins B7 (‘nucleotide and amino acid metabolism’ pathway; 
M00573, M00577 and M00123) were also increased in all time points 
up to 14 months in non-breastfed infants, a function that is associated 
with the adult microbiome28.
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Fig. 3 | Breastfeeding status was the most significant microbiome 
covariate associated with all datasets throughout the first year of life. 
Breastfeeding status was significantly associated with microbiome profiles 
over the first three time points (months 3–14, n = 2,257; Supplementary 
Table 1). Curves show locally weighted scatterplot smoothing (LOESS) 
for the data per category, and shaded areas show permutation-based 95% 
confidence intervals for the fit. a, Non-metric multidimensional scaling 
(NMDS) ordination plots showing the mean centroid of each breastfeeding 
status group. Plots include only the first sample obtained from a patient 
within a given time point; months 3–6, 7–10 and 11–14. Centroid size 
based on number of samples and the bars represent the ±95% confidence 
interval. b, Plots showing the receipt of breast milk from months 3 to 40  
of age compared to the relative abundance of the six most abundant 
Bifidobacterium species over the same period (n = 11,717). c, Longitudinal 
Shannon diversity index from months 3 to 40 of age (n = 11,717).  
d, Longitudinal development of the microbiome maturation based on the 
microbiota age and MAZ score against the age of the infant at sampling 
(n = 11,717). e, Heat map showing the mean abundance of all significant 
modules as determined by MaAsLin analysis at each of the first three time 
points. The corresponding pathway for each module is also presented. BM, 
breast milk. f, Stacked bar plots showing the abundance of each significant 
module binned at the pathway level. Abundance plotted per bacterial 
species, with the five most significant species associated with breastfed and 
non-breastfed infants, respectively.
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By mapping reads with genomic coordinates that overlap with known 
KEGG orthologues to KEGG modules (M), we were able to directly 
determine from which taxa each gene orthology (and thus module) 
was derived (see Methods). Each pathway from which each significant 
module was derived was plotted against the main species discriminat-
ing breastfeeding status (Supplementary Table 2). In breastfed infants, 
B. breve accounted for the highest number of significant modules in 
early life, and was replaced by B. bifidum after 6 months of life (Fig. 3f). 
In non-breastfed infants, E. coli primarily accounted for the signifi-
cant modules between 3 and 14 months of life (Fig. 3f). This provides 
further evidence that the gut microbiome rapidly matures after the 
cessation of breast milk, both at the taxonomic and functional levels.
The TEDDY study was powered to detect microbiome associations 
with the development of IA and T1D based on a specific 1:1 nested 
case–control study design, from two nested case–control studies (IA 
or T1D), using risk set sampling29. The analytical cohort consisted of 
a subset with an equal number of samples for each case–control pair. 
The IA cohort consisted of 632 children and 6,194 stool samples and 
the T1D cohort consisted of 196 children and 1,540 stool samples, as of 
31 May 2012 (Supplementary Table 3). The temporal alpha diversity 
(both richness and Shannon’s diversity), microbiota age and MAZ 
scores were comparable between cases and matched controls for both 
the IA and T1D groups (all P > 0.05; Extended Data Fig. 4a–h). The 
relative abundance of the top 50 most abundant genera from 16S 
rRNA gene sequencing showed only subtle compositional differences, 
with higher relative abundance of an unclassified Erysipelotrichaceae 
(P = 0.019) in cases of IA (Supplementary Table 3). In the T1D and 
control cohort, five bacterial genera were associated with T1D onset, 
with Parabacteroides the most significant (P < 0.001). Eleven bac-
terial genera were lower in T1D cases, including four unclassified 
Ruminococcaceae, Lactococcus (P = 0.020), Streptococcus (P = 0.032), 
and Akkermansia (P = 0.045) (Supplementary Table 3).
Conditional logistic regression models showed no significant associa-
tions between either the numbers of unique states exhibited or the num-
ber of transitions between different states per subject for IA (Extended 
Data Fig. 4i and Supplementary Table 3). The lack of associations was 
consistent in T1D, with the exception that cases exhibited fewer unique 
states 6–12 months before the onset of T1D (P = 0.032) (Extended Data 
Fig. 4j and Supplementary Table 3). Notably, the 6–12 months before 
T1D onset group consisted of the lowest number of samples for any of 
the time points (n = 67 subjects per group), and thus the statistically 
significant result should be interpreted with caution. Overall, the con-
ditional logistic regression models of community dynamics suggest that 
microbiome stability was not strongly related to the onset of IA or T1D.
Further analysis of covariates that were significant at several time 
points and/or consistently significant by 16S rRNA gene sequencing 
and metagenomics are presented in Supplementary Note 3. In brief, 
birth mode was significantly associated with microbiome develop-
ment over the first year of life, with higher levels of Bacteroides spp. 
in infants that were delivered vaginally (Extended Data Fig. 5). This 
was generally consistent across the different breast milk exposure 
groups and geographical locations (Extended Data Fig. 6). Differences 
between geographical locations occurred from 3 to 22 months of life 
(Supplementary Table 1), although the core microbiome was consist-
ent (Supplementary Table 4), and diversity, microbiota age and MAZ 
scores had comparable trajectories across each location (Extended Data 
Fig. 7a–c). Household exposures (for example, living with siblings and 
with furry pets) were also associated with differences in the microbi-
ome profiles in early life, in which infants living with siblings and/or 
with furry pets showed accelerated rates of maturation of the microbi-
ome (Extended Data Fig. 7d–i).
The TEDDY population offers a robust analysis of gut microbiome 
development of 903 infants from months 3 to 46 of age, with regular 
sampling (more than 12,000 stool samples), extensive metadata, and 
the use of both amplicon and metagenomic sequencing. We showed 
that the first year of life is a key phase for the development of the 
microbiome, with the receipt of breast milk being the main factor that 
influences microbiome development over this period. Birth mode, 
geographical location, household siblings and furry pets were also 
associated with the microbiome over this period. We considered the 
first year of life as developmental, the second year of life as transitional, 
and from year three of life the microbiome stabilized. These precise 
ages may shift when investigators include samples before month 3 or 
beyond month 46 of life.
The current cohort is largely white, non-Hispanic and is drawn from 
a population of infants at high genetic risk for T1D, some of whom 
developed autoimmunity or diabetes. Temporal alpha diversity and 
community dynamics were comparable between cases and controls, 
which is in contrast to findings reported in other cohorts and may 
reflect the increased number of subjects and samples in the TEDDY 
cohort11,12. We found subtle changes in the relative abundance of bac-
terial genera between cases (IA and/or T1D) and matched controls. 
T1D cases showed higher levels of Streptococcus sp. and Lactococcus 
sp., which is consistent with the findings of Vatanen et al.14 in the com-
panion paper. In accordance with previous work, the abundance of 
Akkermansia was also higher in controls in the current study, which 
may be indicative of enhanced gut integrity10.
The overall microbiome development and significant covariates 
are in concordance with previous reports in westernized populations, 
although caution should be exercised when extrapolating the findings 
from the TEDDY cohort of children with risk factors of developing 
T1D to the wider population. Nevertheless, the significant covariates 
reported in the current study have been independently linked to the 
risk of later life diseases such as obesity, asthma and allergy1–8. The 
current study provides several testable hypotheses of microbiome 
development in infancy, and it remains important to determine the 
potential mechanism of altered early life microbiome and the subse-
quent effect on immune development and functioning. With a more 
comprehensive understanding of the crucial early life phases and their 
effect on health and disease, lifestyles and therapeutics can be tailored 
to support optimal microbial–immune homeostasis.
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MEthOdS
Study population. The TEDDY Study is composed of six clinical research cen-
tres: three in the United States (Colorado, Georgia/Florida and Washington), and 
three in Europe (Finland, Germany and Sweden). Children enrolled are followed 
prospectively from three months to 15 years with study visits every three months 
until age 4 years and every three or six months thereafter depending on autoan-
tibody positivity. Stool samples and associated metadata were collected as of 
31 May 2012. Stool samples were collected monthly from 3 to 48 months of life, 
then every three months until the age of 10 years, and then biannually thereafter, 
into the three plastic stool containers provided by the clinical centre. Children who 
were antibody negative after 4 years of age were encouraged to submit four times 
a year even though after 4 years their visits schedule switched to biannual. Parents 
sent the stool containers at either ambient or +4 °C temperature with guaranteed 
delivery within 24 h in the appropriate shipping box to the NIDDK repository if 
living in the United States or their affiliated clinical centre if living in Europe. The 
European clinical centres stored the stool samples and sent monthly bulk shipments 
of frozen stool to the NIDDK repository. The population (both cases and controls) 
is based on children at high risk for T1D based on their HLA genotype with 10% 
based on family history in addition to HLA. Detailed study design and methods 
have been previously published13,29,30. Matching factors for case and control 
children were geographical location, sex and family history of T1D.
Metadata were collected using validated questionnaires that have been either 
published or extensively scrutinized by experts. Information about mothers, preg-
nancy and birth was collected during the three month clinic visit by question-
naire and included the mode of birth (vaginal birth versus Caesarean section), the 
infant’s 5-min Apgar score, pregnancy complications, information about maternal 
diabetes (T1D, type 2 diabetes (T2D) or gestational diabetes), gestational age, and 
maternal medication use (insulin, metformin, glyburide, antihypertensives) during 
pregnancy. TEDDY provides many tools, such as ‘The TEDDY book’, to the parents 
to assist in real-time collection of all events in their child’s life to ensure bias and 
error are minimized. At each visit the study personnel will go over the TEDDY 
book with the primary caretaker and extract pertinent information using stand-
ardized study forms. Data are extracted by trained staff members during scheduled 
visits every three months starting at 3 months of age and entered directly via stand 
forms (web forms or teleforms), which are transmitted electronically. Front-end 
constraints are used in the web application to prevent the entry of invalid data and 
The TEDDY Error Reporting and Verification System (ERVS) consists of a set of 
programs that conduct automated quality control on the data, report and resolve 
errors, an integrated database for storing error data, and a set of programs that 
generate reports for monitoring data cleaning efforts. The details of the system 
have been published31. Given the prospective nature of the TEDDY design, infor-
mation and recall bias are greatly minimized. Because the children do not have 
event outcome at time of enrolment and are followed, there is no reason for any 
systematic differences between groups of the study participants in the accuracy of 
the information collected.
The TEDDY study was approved by local US Institutional Review Boards 
and European Ethics Committee Boards in Colorado’s Colorado Multiple 
Institutional Review Board, Georgia’s Medical College of Georgia Human 
Assurance Committee (2004–2010), Georgia Health Sciences University Human 
Assurance Committee (2011–2012), Georgia Regents University Institutional 
Review Board (2013–2015), Augusta University Institutional Review Board 
(2015–present), Florida’s University of Florida Health Center Institutional Review 
Board, Washington state’s Washington State Institutional Review Board (2004–
2012) and Western Institutional Review Board (2013–present), Finland’s Ethics 
Committee of the Hospital District of Southwest Finland, Germany’s Bayerischen 
Landesärztekammer (Bavarian Medical Association) Ethics Committee, Sweden’s 
Regional Ethics Board in Lund, Section 2 (2004–2012) and Lund University 
Committee for Continuing Ethical Review (2013–present). All parents or guard-
ians provided written informed consent before participation in genetic screening 
and enrolment. The study was performed in compliance with all relevant ethical 
regulations.
A priori power calculations using discrete Cox’s proportional hazards regres-
sion32 for the matched IA case–control study estimated 80% power, α = 0.01, two-
sided test to detect an odds ratio > 3 for an exposure with 5% prevalence to an 
odds ratio > 1.8 for an exposure with 20% prevalence. The experiments were not 
randomized, and investigators were not blinded to allocation during experiments 
and outcome assessment.
16S rRNA gene sequencing. 16S rRNA gene sequencing methods were adapted 
from the methods developed by the NIH-Human Microbiome Project and the 
Earth Microbiome Project33–35. Bacterial DNA was extracted using the PowerMag 
Microbiome DNA isolation kit following the manufacturer’s instructions. The V4 
region of the 16S rRNA gene was amplified by PCR and sequenced on the MiSeq 
platform (Illumina) using the 2 × 250 bp paired-end read protocol. The read 
pairs were demultiplexed and reads were merged using USEARCH v7.0.109036. 
Merging allowed zero mismatches and a minimum overlap of 50 bases, and merged 
reads were trimmed at the first base with a q ≤ 5. A quality filter was applied 
to the resulting merged reads and those containing above 0.5% expected errors 
were discarded. Sequences were stepwise clustered into OTUs at a similarity cut-
off value of 97% using the UPARSE algorithm37. Chimeras were removed using 
USEARCH v7.0.1090 and UCHIME v4.2. To determine taxonomies, OTUs were 
mapped to a version of the SILVA Database38 containing only the 16S V4 region 
using USEARCH v7.0.1090. Abundances were recovered by mapping the merged 
reads to the UPARSE OTUs. A custom script constructed a rarefied OTU table 
from the output files generated in the previous two steps for downstream analyses 
of taxonomic relative abundance, alpha diversity, and beta diversity (including 
UniFrac)39. A total of 114,313,601 reads (median 8,442 reads per sample) were 
obtained from 16S rRNA gene sequencing and each sample was rarefied to 3,000 
reads. Stringent merging parameters account for the relatively low number of 
OTUs, with the number of species by metagenomics around fourfold higher than 
the number of OTUs by 16S rRNA gene sequencing.
Metagenomic shotgun sequencing. Individual libraries constructed from each 
sample were pooled and loaded onto the HiSeq 2000 platform (Illumina) and 
sequenced using the 2 × 100 bp paired-end read protocol. The process of quality 
filtering, trimming, and demultiplexing was carried out by in-house pipeline 
developed by assembling publicly available tools such as Casava v1.8.2 (Illumina) 
for the generation of fastqs, Trim Galore v0.2.8 (http://www.bioinformatics. 
babraham.ac.uk/projects/trim_galore/) and cutadapt v1.9dev2 for adaptor and 
quality trimming, and PRINSEQ v0.20.540 for sample dereplication and low com-
plexity filtering. In addition, Bowtie2 v2.2.341 was used to map reads to a database 
containing complete genomes and assemblies for bacteria, viruses, human, and 
vectors in the NCBI whole-genome sequencing (WGS) archive (as of March 2015). 
Reads in which the highest identity matches were not bacterial were removed from 
subsequent analysis. The edit distance (Levenshtein distance) was used to deter-
mine the score of the alignments to the reference genomes42. For bacterial reads, 
the highest scoring match (greater than 90%) was chosen per read considering 
only the top 25 highest scoring alignments. In the event of multiple identical top 
scoring hits, the lowest common ancestor was determined.
Reads in which the genomic coordinates overlap with known KEGG ortho-
logues43,44 were tabulated, and KEGG modules were calculated step-wise and 
determined to be complete if 65% of the reaction steps were present per detected 
species and for the metagenome. Pathways were constructed for each taxa and 
metagenome by calculating the minimum set through MinPath45 resulting from 
the gene orthologues present. A total of 19,967,936,136 reads (median 1,606,240 
reads per sample) were obtained from metagenomic sequencing and for subse-
quent analysis each sample was rarefied to 100,000 reads.
Statistical analysis. The analysis was conducted in two parts: (1) characterize 
the longitudinal maturation of the microbiome and (2) determine the significant 
covariates that influence microbiome development. For both parts of analysis, 
alpha diversity (richness and Shannon diversity) was calculated at the OTU-level 
for 16S rRNA gene sequencing and species-level for metagenomics data. Alpha 
diversity and taxonomic abundance were modelled using LOESS regression, 
and implemented and plotted with 95% confidence intervals in R (http://www. 
R-project.org) using the ggplot package46.
DMM clustering. The first part of the analysis determined the key phases of micro-
biome progression, which included the use of DMM. DMM bins samples on the 
basis of microbial community structure47. The appropriate number of clusters was 
determined based on the lowest Laplace approximation score. For this specific 
analysis, samples up to month 46 of life were included, whereas all other analyses 
included samples up to month 40 of life. Including the additional samples here 
allowed for more accurate determination of the microbiome phases.
The second part of the analysis sought to determine the significant covariates in 
shaping the microbiome profiles at discrete time points and further ascertain the 
significantly altered taxa based on samples up to month 40 of life. The framework 
for the statistical analysis considered the longitudinal nature of the dataset and 
accounted for the dynamic nature of the covariates. Owing to the potential that 
some covariates might influence the microbiome before the start date (for example, 
underlying indication for an antibiotic prescription) and some covariates will alter 
the microbiome for an unknown time frame (for example, microbiome disrupted 
by antibiotics may continue to be altered months after treatment), covariates were 
classified as ‘before’, ‘during’, or ‘after’. In the case a covariate was negative for an 
infant, all samples would be classified as ‘never’. In instances in which several onsets 
of a covariate were possible (for example, multiple antibiotic start and end time 
points), after the first onset the covariate was classified as ‘after’ for the remaining 
samples, unless another event occurred, in which case ‘during’ would be applied 
where appropriate according to the start and stop dates. Analysis was performed 
at specific time windows, including samples collected between months 3–6, 7–10, 
11–14, 15–18, 19–22, 23–26, 27–30 and 31–40. Only the first sample collected from 
a given child was included in each time window to account for repeated measures.
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EnvFit analysis to determine significant covariates. The effect size and significance 
of each covariate were determined using the ‘envfit’ function in ‘vegan’ (https://
cran.r-project.org/web/packages/vegan/index.html) comparing the difference in 
the centroids of each group relative to the total variation. Ordination was per-
formed using NMDS based on Bray–Curtis dissimilarity. The significance value 
was determined based on 10,000 permutations. All P values derived from envfit 
were adjusted for multiple comparisons using FDR adjustment (Benjamini–
Hochberg procedure)48. In total, 22 covariates with known associations to gut 
microbiome development in neonates, infants, and children were included in 
the envfit analysis and the grouping used for within each variable is presented in 
Extended Data Table 1. Specifically, we tested maternal factors including diabe-
tes (gestational, T1D, T2D or none)49, diabetes medication (insulin, metformin, 
glyburide, antihypertensives)50, BMI51,52, gestational weight gain category (excess 
or non-excess)53, preeclampsia52, maternal probiotic consumption54, as well as 
offspring factors such as prematurity18,55, birth mode15–17,56, gender56, receipt of 
breast milk and/or formula17,53,57–59, introduction of solid foods60,61, geographical 
location57, probiotics62, vitamin D supplementation63, antibiotics18, household 
siblings56,64, household furry pets64,65, living on a farm with animals66,67, day-care 
exposure68, coeliac disease69, acute disease, and chronic disease69.
MaAsLin analysis to determine significant taxa associated with each covariate. 
MaAsLin was used for adjustment of covariates when determining the signifi-
cance of taxa (genus level for 16S rRNA gene sequencing and species level for 
metagenomic sequencing) contributing to a specific variable, while accounting 
for potentially confounding covariates70. In brief, this multivariate linear mod-
elling system for microbial data selects from among a set of (potentially high- 
dimensional) covariates to associate with microbial taxon or pathway abundances. 
Mixed-effects linear models using a variance-stabilizing arcsin square root trans-
form on relative abundances are then used to determine the significance of putative 
associations from among this reduced set. Nominal P values across all associations 
are then adjusted using the Benjamini–Hochberg FDR method. Here, microbial 
features with corrected q < 0.25 were reported. All 22 covariates tested in the envfit 
were included in the adjustment regardless of significance by envfit. Subject age 
was also included to adjust for potential age driven changes in taxa within each 
three-month time window and IA and T1D outcome were included to adjust for 
the nested case control nature of the cohort. The default MaAsLin parameters 
were applied (maximum percentage of samples NA in metadata 10%, minimum 
percentage relative abundance 0.01%, P < 0.05, q < 0.25). All P values were adjusted 
for multiple comparisons using FDR48.
Microbiota maturation modelling and linear mixed-effects analysis. The random 
forest regression model71 was performed as previously described25, using the ‘ran-
domForest’ R package72. In brief, the model was trained on 150 randomly selected 
full term (>37 weeks gestation), vaginally delivered, breastfed infants who had a 
minimum of 10 samples included in the final dataset. The model was built using 
the default parameters: growing 10,000 trees and n/3 OTUs randomly sampled 
at each split, in which n represents the number of OTUs. The model was further 
refined by applying ‘rfcv’ with tenfold cross-validation resulting in the inclusion of 
20 OTUs to train the final model based on percentage increase in mean-squared 
error. These 20 OTUs explained 72% of the total variance of the model (compared 
to 75% with all OTUs included). The age of the subject predicted by this model was 
termed microbiota age and was further used to determine MAZ scores using the 
formulae described preiously25. Significant differences in alpha diversity, microbi-
ota age, and MAZ scores were calculated using linear mixed-effects models in R, 
with the ‘lmer’ command within the ‘lme4’ package73. We included random slopes 
and intercept for individual children, and evaluated delivery mode, age, Bacteroides 
positive or negative, predominant diet, geographical location, presence of 
siblings, and presence of household pets as fixed effects. To perform these piecewise 
longitudinal models, we divided samples into the three developmental phases 
(<14 months, >15–<30 months, and >31 months). Owing to the relatively low 
number of samples in the exclusive and never breastfed groups, the analysis of 
breast milk status was conducted based on ‘some breast milk’ or ‘after breast milk’, 
with these groups found to cluster with exclusive and never breastfed, respectively.
Determination of the datasets for IA and T1D nested case–control stability analyses. 
The development of persistent confirmed IA was assessed every three months. 
Persistent autoimmunity was defined by the presence of confirmed islet autoanti-
body on two or more consecutive visits. The date of persistent autoimmunity was 
defined as the draw date of the first sample of the two consecutive samples that 
deemed the child persistent confirmed positive for a specific autoantibody (or 
any autoantibody). T1D was defined according to American Diabetes Association 
criteria for diagnosis74. A dataset with equal numbers of cases and control samples 
was created to preform conditional logistic regression of summary metric variables 
(that is, counting for each person the number of unique clusters exhibited and 
the number of temporal transitions between different clusters). On average, cases 
tended to have more samples than controls, and therefore had more transitions 
and observed states, which resulted in spurious associations between our metrics 
and disease outcome. For this purpose, we created a dataset in which case and 
control samples were matched to the paired case based on the nearest sample by 
day of life (unmatched sample or sample outside of ±20% were omitted from anal-
yses). This resulted in an analytical cohort of 316 IA cases and 316 paired controls 
(n = 3,097 stool samples in each group) and 98 T1D cases and 98 paired controls 
(n = 1,270 stool samples in each group). For consistency, we used these datasets 
for all matched case–control analyses. The IA and T1D analysis was based on 16S 
rRNA gene sequencing data only and analysis of the metagenomic sequencing data 
(that is, species level taxonomic profiling and functional capacity) are presented 
in the companion paper14.
Taxonomic and metabolic profiling relative to IA onset in the matched case–control 
dataset. 16S rRNA gene sequencing data was used to determine differences 
between alpha diversity (number of OTUs (richness) and Shannon’s diversity 
index), microbiota age, and MAZ scores. Significant differences in alpha diver-
sity, microbiota age, and MAZ scores were calculated using linear mixed-effects 
models in R, with the ‘lmer’ command within the ‘lme4’ package73. To perform 
these piecewise longitudinal models, we divided samples into the three develop-
mental phases (<14 months, >15–<30 months, and >31 months). Conditional 
logistic regression of matched case–control pairs was performed on the top 50 most 
dominant bacterial genera from samples prior to disease diagnosis. Odds ratios 
were calculated with 95% confidence intervals, adjusted for potential confounding 
variables, including age at sample collection, HLA genotype, mode of delivery, and 
duration of breastfeeding. Abundance information for genera was entered into the 
model as log2-transformed read counts. A value of 0.01 was added to avoid 0 s. The 
Benjamini–Hochberg procedure was applied to correct for multiple comparisons48 
and corrected P < 0.05 was considered significant.
Assessment of microbiome instability based on DMM clusters between IA or T1D 
cases and controls. For each subject, the total number of clusters exhibited through-
out sampling per infant and the number of transitions between different clusters 
from one sample to the next were calculated to provide summary measures of 
microbiome stability over time. These summary metrics were then used in con-
ditional logistic regression to assess the relationship of microbiome stability with 
IA and T1D. Odds ratios were calculated with 95% confidence intervals, adjusted 
for potential confounding variables, including HLA genotype, mode of delivery, 
duration of breastfeeding, number of antibiotic courses, and number of infectious 
episodes.
Reporting summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this paper.
Code availability. Code for the transition model showing the progression of 
samples through each DMM cluster, which are presented in Fig. 1 and Extended 
Data Fig. 2, has been made publicly available at https://github.com/StewartLab/
Stewart_TEDDY_Microbiome_Analysis. Other analysis software including quality 
control, taxonomic, and functional profilers is publicly available and referenced 
as appropriate.
Data availability
TEDDY microbiome 16S rRNA gene sequencing and metagenomic sequencing data 
that support the findings of this study have been deposited in the NCBI database of 
Genotypes and Phenotypes (dbGaP) with the primary accession code phs001443.
v1.p1, in accordance with the dbGaP controlled-access authorization process. 
Clinical metadata analysed during the current study will be made available in the 
NIDDK Central Repository at https://www.niddkrepository.org/studies/teddy.
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Extended Data Fig. 1 | Characterization of the gut microbiome over 
the first 40 months of life (n = 11,717). a–d, 16S rRNA gene sequencing 
(a–c) and metagenomic sequencing (d) analysis. Curves show LOESS fit 
for the data per category, and shaded areas show permutation-based 95% 
confidence intervals for the fit. a, Summary of overall dietary status. b, The 
mean alpha diversity (richness and Shannon diversity) per child increased 
rapidly from 3 to 20 months of life. c, The mean relative abundance of the 
five most abundant bacterial phyla show changes from 3 to 20 months of 
life and generally remain stable after month 30 of life. d, The mean relative 
abundance of the ten most abundant bacterial pathways shows relative 
stability, with ABC transporters and two-component system showing the 
largest reduction from 3 to 20 months of life.
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Extended Data Fig. 2 | DMM clustering of metagenomic sequencing 
data (n = 10,867). The entire dataset formed 18 distinct clusters based 
on lowest Laplace approximation. a, Heat map showing the relative 
abundance of the 25 most dominant bacterial species per each DMM 
cluster. b, Box plots showing the alpha diversity (richness and Shannon’s 
diversity) for each DMM cluster. The centre line shows the median, the 
boxes cover the 25th and 75th percentiles, and the whiskers extend to 
the most extreme data point, which is no more than 1.5 times the length 
of the box away from the box. Points outside the whiskers represent 
outlier samples. c, Transition model showing the progression of samples 
through each DMM cluster per each time point, from months 3 to 46 
of life. Dashed boxes show the three phases of microbiome progression 
(developmental, transitional and stable phase). Solid squares next to the 
labels denote the significant changes in phyla and Shannon diversity 
(H') per phase based on multiple linear regression. All phyla and the H' 
were significant in the developmental phase, two phyla and the H' were 
significant in the transitional phase, and no phyla or the H' were in the 
stable phase. Nodes and edges are sized based on the total counts. Nodes 
are coloured according to DMM cluster number and edges are coloured 
by the transition frequency. Transitions with less than 2% frequency were 
omitted from the plot.
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Extended Data Fig. 3 | Twenty bacterial OTUs classified by random 
forest regression analysis as most age discriminatory over the first 
40 months of life. Rank importance of OTUs determined by applying 
the random forest regression to the chronological age of 150 full-term, 
vaginally delivered, breastfed infants (n = 2,871 stool samples). The 
importance of OTUs is determined by the percentage increase in mean-
squared error of microbiota age prediction when the relative abundance 
of each OTU were randomly permuted (mean importance ± s.d., 
n = 100 replicates). These selected OTUs explained 72% of the variance 
(compared to 75% variance explained with all OTUs in model) and were 
used to define maturation of the gut microbiome by microbiota age and 
MAZ score. OTUs are named to the genus level and coloured based on 
association with life stage; blue were associated with samples collected 
in the first 15 months, green with samples collected between months 15 
and 30, and red were with samples collected after month 30. a, Twenty 
OTUs ranked by importance to the accuracy of the model. The tenfold 
cross-validation error is also displayed in order of variable importance. 
Blue dotted line represents the 20 OTUs used in the model. b, Heat map 
of mean relative abundance of the 20 selected OTUs per month from 3 to 
40 months of age.
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Extended Data Fig. 4 | The microbiota was not associated with the 
development of persistent IA and T1D. Data are based on 16S rRNA 
gene sequencing (n = 11,717). Analysis based on a nested 1:1 case–control 
cohort of equal samples. Curves show LOESS fit for the data per category, 
and shaded areas show permutation-based 95% confidence intervals for 
the fit. a, b, The number of OTUs (a) and the Shannon’s diversity index (b) 
in the IA cohort. c, d, The number of OTUs (c) and Shannon’s diversity (d)  
in the T1D cohort. e, f, Microbiota age (e) and MAZ score (f) in the IA 
cohort. g, h, Microbiota age (g) and MAZ score (h) in the T1D cohort. 
i, j, Forest plot showing the odds ratios for the association between the 
microbiome stability metrics and development of IA (i) and T1D (j).  
A separate conditional logistic regression was run for four time intervals: 
(1) birth to onset; (2) 12 months before onset; (3) 6–12 months before 
onset; and (4) 6 months before onset. Models were adjusted for HLA 
genotype, mode of delivery, duration of exclusive breastfeeding, number of 
antibiotic courses, and number of infectious episodes. Community states 
are the total number of unique clusters exhibited by an infant and state 
transitions are the number of transitions between clusters. No odds ratio 
was significantly different between cases and controls (Supplementary 
Table 3).
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Extended Data Fig. 5 | Association of the gut microbiome with birth 
mode. Birth mode was significantly associated with the microbiome 
in months 3–6 by 16S rRNA gene sequencing and in all time points up 
to month 14 by metagenomic sequencing (see Supplementary Table 1). 
Curves show LOESS fit for the data per category, and shaded areas show 
permutation-based 95% confidence intervals for the fit. a, Longitudinal 
development of the Bacteroides genus as determined by 16S rRNA 
gene sequencing (n = 11,717). b, Longitudinal development of the six 
most abundant species within the Bacteroides genera as determined by 
metagenomic sequencing (n = 10,867). Grid overlay added to aid visual 
interpretation. c, NMDS ordination plots showing the mean centroid 
of each birth mode group stratified by Bacteroides positive or negative 
based on detection 16S rRNA gene sequencing. Plots include only the first 
sample obtained from a patient within a given time point for months 3–6, 
7–10 and 11–14 (n = 2,257). Centroid size based on number of samples 
and the bars represent the ±95% confidence interval. d, Longitudinal 
development of the alpha diversity (richness and Shannon’s diversity) with 
birth mode further stratified according to Bacteroides positive or negative 
(n = 11,717). e, Longitudinal development of the microbiome maturation 
based on the microbiota age and MAZ score against the age of the infant 
at sampling (n = 11,717). Birth mode was further stratified according to 
Bacteroides positive or negative.
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Extended Data Fig. 6 | The relative abundance of Bacteroides stratified 
by breast milk and geographical location. Curves show LOESS fit for 
the data per category, and shaded areas show permutation-based 95% 
confidence intervals for the fit. a, b, Bacteroides genera based on 16S rRNA 
gene sequencing data (n = 11,717) stratified by breast milk status (a)  
and geographical location (b). c, The top 6 Bacteroides species based on 
metagenomic sequencing data (n = 10,867) stratified by geographical 
location.
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Extended Data Fig. 7 | Environmental covariates significantly 
associated with the microbiome profiles. 16S rRNA gene sequencing 
data plotted from months 3–40 of life (n = 11,717). Curves show LOESS 
fit for the data per category, and shaded areas show permutation-based 
95% confidence intervals for the fit. Significance determined by linear 
mixed-effects models in accordance with observed phases of maturation: 
developmental (months 3–14), transitional (months 15–30), and stable 
(months 31–46). Shaded lines represent the ±95% confidence interval. 
Longitudinal development of the Shannon’s diversity index, microbiota age 
and MAZ score by geographical location (a–c), occurrence of household 
siblings (d–f), and occurrence of household furry pets (g–i).
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Extended data table 1 | Overview of the entire analytical cohort
IQR, interquartile range; NA, not available.
*Maternal variables relate to measurements obtained during pregnancy.
**Race/ethnicity was only available for the US sites.
© 2018 Springer Nature Limited. All rights reserved.
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Sample size Longitudinal stool samples between months 3-46 of life from 903 children were analyzed by 16S rRNA gene sequencing (n=12,005) and 
metagenomic sequencing (n=10,867). The cohort is a nested case-control design.
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Replication Observational cohort.  No replication 
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Population characteristics Children were aged 3-46 months for the analysis. Children samples were obtained from six geographical locations (Finland, 
Germany, Sweden in Europe and Washington, Colorado and Georgia in the United States). The cohort is at high risk for 
developing IA or T1D, with half of the cohort cases and the other half controls.
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